CagriSema 2.4 mg yields incremental body weight reduction over semaglutide in Type 2 diabetes.

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia, often accompanied by obesity. Current treatments, including basal insulin, frequently fall short in achieving optimal glycemic control and can lead to weight gain. The combination of cagrilintide, an amylin receptor agonist, and semaglutide, a GLP-1R agonist, offers a promising approach. These agents have complementary mechanisms, with GLP-1R activation improving glucose-dependent insulin secretion and amylin receptor agonism enhancing satiety and slowing gastric emptying, addressing both glycemic control and body weight management gaps in T2D.

This systematic review and Bayesian meta-analysis synthesized data from six randomized controlled trials (RCTs) involving 4554 participants with Type 2 diabetes. Researchers searched PubMed, Embase, CENTRAL, and ClinicalTrials.gov for studies through June 2026. Analyses were stratified by CagriSema dose and comparator (placebo or semaglutide 2.4 mg). Primary endpoints included changes in HbA1c and percentage body-weight change. Efficacy estimands were aligned where possible, with treatment-policy estimates used in sensitivity analyses. Bayesian random-effects models generated posterior medians and 95% credible intervals (CrIs).

Written by TitrateLab, separately from the study summarized above.